Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 306.50
Bid: 309.00
Ask: 310.50
Change: -8.50 (-2.70%)
Spread: 1.50 (0.485%)
Open: 311.50
High: 312.50
Low: 302.00
Prev. Close: 315.00
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Biomedica swings to EBITDA profit

Thu, 15th Apr 2021 09:02

(Sharecast News) - Oxford Biomedica reported a 37% improvement in total revenues in its preliminary results on Thursday, to £87.7m.
The FTSE 250 company said bioprocessing and commercial development revenues increased 45% to £68.5m for the year ended 31 December, with double digit growth across both activities, driven by new customers AstraZeneca, Beam Therapeutics and Juno/BMS.

Revenues from licences, milestones and royalties increased to £19.2m from £16.8m in the prior year, due to the recognition of a £7.8m licence fee from Juno/BMS as well as other licence fees, milestones and royalties from customers.

Operating expenses increased by less than revenues, rising 23% to £51.7m, aided by the move to the lower-cost bioreactor manufacturing process.

The firm swung to an operating EBITDA profit of £7.3m from a loss of £5.2m in 2019, which was marginally above its guided range.

Its operating loss, meanwhile, narrowed to £5.7m from £14.5m.

The company's platform segment generated an operating profit of £2m, compared to a £20.2m loss a year earlier, while the product segment made a loss of £7.7m, swinging from a £5.7m profit in 2019.

Capital expenditure decreased to £13.4m from £25.8m, which the board said was primarily due to the Windrush Court laboratory conversion and equipment purchases, and leasehold improvements at Oxbox.

Cash at year-end stood at £46.7m, up from £16.2m at the end of 2019, and had reached £65.9m by 31 March.

Oxford Biomedica said cash used in operations totalled £3.9m for the year, falling from £6.6m as a result of the increased revenues, offset by further operational investments.

The company undertook a successful £38.3m equity fundraise in June, to exploit the growth in the cell and gene therapy market.

"We not only secured major new partnerships, brought the Oxbox manufacturing facility online in record time and responded to the challenges of the pandemic, but the team has also been able to rapidly work with AstraZeneca to provide a vaccine solution for Covid-19," said chief executive officer John Dawson.

"This is a true testament to the world-class calibre and dedication of our staff in the year that the group also gained entry to the FTSE 250.

"Looking to the future, with the continued tide of growth in cell and gene therapy, coupled with the group's leadership position in the lentiviral vector field, we are well positioned to advance both our own proprietary pipeline and that of our current and future partners' programmes."

At 0844 BST, shares in Oxford Biomedica were up 0.43% at 1,044.48p.
More News
29 Apr 2016 12:54

DIRECTOR DEALINGS: Oxford Biomedica Executive Director Buys Shares

Read more
28 Apr 2016 08:37

Oxford Biomedica Loss Widens As Research Spending And Staff Grow

Read more
25 Apr 2016 08:29

DIRECTOR DEALINGS: Oxford BioMedica Chairman Ups Interest

Read more
21 Apr 2016 15:05

Earnings, Trading Statements Calendar - Week Ahead

Read more
4 Apr 2016 06:39

IXICO Enters Parkinson's Consortium And Secures Oxford Biomedica Deal

Read more
24 Mar 2016 11:14

DIRECTOR DEALINGS: Oxford Biomedica Chairman Ups Interest

Read more
7 Mar 2016 09:25

Oxford BioMedica Expands Collaboration, Inks Deal With Immune Design

Read more
25 Feb 2016 18:03

DIRECTOR DEALINGS: Oxford BioMedica Chairman Buys First Shares

Read more
23 Feb 2016 12:23

Oxford Biomedica to raise £8.1m in placing

(ShareCast News) - Biopharmaceutical company Oxford Biomedica plans to raise £8.1m in a placing of 128.4m shares at 6.3p with new and existing investors. The placing, which is priced at a 10% discount to the 7p closing price on 22 February, is to provide adequate working capital for the group to con

Read more
23 Feb 2016 08:26

Oxford BioMedica To Raise GBP8.1 Million In Discounted Placing (ALLISS)

Read more
29 Jan 2016 08:09

Oxford Biomedica Starts New Programme Under Novartis Deal

Read more
13 Jan 2016 08:43

Oxford Biomedica Gets UK Bulk Drug Manufacturing Approvals

Read more
15 Dec 2015 08:57

Oxford Biomedica Names Lorenzo Tallarigo As New Chairman

Read more
4 Nov 2015 10:42

Oxford BioMedica Making Progress On Strategy And Clinical Trials

Read more
28 Oct 2015 08:49

Oxford Biomedica Says Glaxo Exercises LentiVector Platform Option

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.